Up and Coming

Up and Coming from Altimmune, Roche and Paradigm

June 17, 2019

This feature highlights changes in clinical research organizations’ personnel.

Zyla Life Sciences has announced the appointment of H. Jeffrey Wilkins as senior vice president and chief medical officer, effective immediately. Dr. Wilkins most recently served as the chief medical officer at Lycera.

Akrevia Therapeutics
Joseph Farmer has been appointed chief operating officer at Akrevia Therapeutics. Prior to joining Akrevia, Farmer was the senior vice president, general counsel and corporate secretary at Tesaro.

Will Brown has been named the chief financial officer at Altimmune. Brown has been serving as the acting chief financial officer since May 2018.

Mersana Therapeutics
Mersana Therapeutics has announced Brian C. DeSchuytner as senior vice president of finance and product strategy. DeSchuytner was previously at Tesaro, where he was vice president responsible for the ZEJULA (niraparib) commercialization.

Hans Bishop has been appointed chief executive officer at Grail and Joshua Ofman has been named chief of corporate strategy and external affairs. Bishop was previously the chief executive officer at Juno Therapeutics. Ofman was most recently at Amgen as senior vice president, global value and access and policy.

Roche has announced that Thomas Schinecker has been promoted to chief executive officer of Roche Diagnostics, effective August 1. Schinecker is currently head of centralized and point-of-care solutions at Roche.

Celsius Therapeutics
Tariq Kassum has been named president and chief executive officer of Celsius Therapeutics. Kassum was formerly the co-founder of Obsidian Therapeutics and served as chief operating officer and head of corporate development.

Signant Health
Signant Health has appointed Lawrence Miller as chief technology officer. Miller was most recently chief security officer for Symphony Communication Services.

Ariel Jasie has been named chief business officer and general counsel at eGenesis. Jasie was previously chief business and strategy officer at Dermavant Sciences.

PMV Pharmaceuticals
PMV Pharmaceuticals has named Deepika Jalota head of regulatory affairs. Jalota was formerly the global regulatory strategy head of Oncology I at Bayer HealthCare Pharmaceuticals.

SCWorx Corp.
Tad Schweikert has been appointed chief operating officer of New York-based SCWorx Corp. Schweikert was most recently a senior principal of enterprise solutions at Vizient.

Paradigm has promoted Kevin Turner to chief executive officer of the Catastrophic Care Management division. Turner previously served as chief sales and marketing officer for Catastrophic Care Management. Karen Jones has been appointed to the newly created role of chief human resources officer. Jones was most recently senior vice president, HR business partner for Experian, Inc.

Steven A. Kates has been named vice president, regulatory affairs at Dicerna. Kates was most recently the director of regulatory affairs at Takeda Pharmaceuticals. David J. Caponera has been appointed head of patient advocacy and patient services. Caponera was formerly vice president, patient engagement and access support at Catalyst Pharmaceuticals.

Freeline has announced the departure of Anne Prener, its chief executive officer. Prener joined the company in 2017. An executive search is underway for the chief executive role. In the interim, Freeline chairman Chris Hollowood will act as executive chairman.